Russian biotechnology company Biocad has initiated clinical trials for BCD-225, a novel drug designed to treat bladder cancer. The development offers a potential new therapeutic option for a cancer that affects a significant number of people worldwide.
According to a statement from Biocad, the primary goal of the Phase I clinical trials is to assess the safety and tolerability of the new drug. “The clinical study is an open, non-comparative Phase I study conducted only in Russia,” the company stated. “The main objective of this phase is to evaluate the safety and tolerability of the drug.”
The trials will as well determine the anticipated therapeutic dosage of BCD-225 when administered directly into the bladder alongside standard treatment with Bacillus Calmette-Guérin (BCG) immunotherapy for patients with non-muscle-invasive bladder cancer, a company source explained.
Combining BCD-225 with BCG is expected to enhance the local anti-tumor immune response in high-risk patients with non-muscle-invasive bladder cancer, who remain at risk of disease recurrence or progression. This approach could improve outcomes for individuals facing this challenging diagnosis.
Bladder cancer is a relatively common malignancy, ranking seventh among all cancers in men and seventeenth in women internationally, according to available data. Approximately 75% of diagnoses are non-muscle-invasive at the time of initial evaluation, Biocad noted.
